跳至主要内容
临床试验/IRCT20231021059793N1
IRCT20231021059793N1尚未招募1 期

Evaluation of efficacy and adverse effects of rivaroxaban in children with central venous catheter thrombosis

Tehran University of Medical Sciences0 个研究点目标入组 20 人开始时间: 待定最近更新:

试验速览

阶段
1 期
状态
尚未招募
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 years 至 18 years(—)
性别
All

入选标准

  • Age 2-18 years old
  • CVC-VTE diagnosed by US Doppler
  • Five days received enoxaparin or heparin

排除标准

  • Active bleeding
  • History of anaphylaxis to rivaroxaban
  • Usage of other anticoagulant drugs including ASA, platelet inhibitors, NSAID, Fibrinolytic, SSRI and SNRI
  • Acutely ill patients with increased risk of bleeding including bronchiectasis, pulmonary cavitation, pulmonary hemorrhage, active cancer, recent HSCT in last 3 months, active GI ulcer or recent GI bleeding in the last 3 months, Liver disease with coagulopathy
  • Patients needing spinal anesthesia or LP
  • Creatinine clearance lower than 30 ml/min
  • Platelet count lower than 75 X 109
  • Dialysis catheter or artificial heart leaflet
  • Unstable hemodynamic

研究者

相似试验

Effect of Rivaroxaban in Thrombosis | 临床试验